Experts at HemeNext 2.0 in Gurugram have called for wider access to genomic testing and advanced blood cancer treatments in India. Discussions focused on how next-generation sequencing, rapid genetic tests and measurable residual disease monitoring can help doctors tailor treatment to individual patients. Specialists also highlighted the cost, infrastructure and safety challenges involved in expanding access to CAR-T cell therapy and bone marrow transplantation. Childhood blood cancers were a major concern, with lymphoid leukaemia accounting for a substantial share of cancers among Indian children. Experts stressed that improving outcomes requires more than advanced treatments: early diagnosis, timely referrals, affordable care and long-term patient support are equally important.
Read more at Firstpost